Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Orexigen Therapeutics Inc. OREXQ

Healthcare Drug Manufacturers - Major
"Orexigen is an emerging pharmaceutical company, focusing on developing neuroscience drugs. The company screens older drugs seeking synergistic actions. The company's most advanced drug candidates target obesity."

Recent & Breaking News (OTCPK:OREXQ)

Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicine

PR Newswire March 15, 2016

Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015

PR Newswire February 26, 2016

Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Full Year 2015 Financial Results on February 26, 2016

PR Newswire February 19, 2016

Orexigen Therapeutics to Speak at the RBC Capital Markets 2016 Healthcare Conference

PR Newswire February 18, 2016

Orexigen Therapeutics to Speak at Upcoming Investor Conferences

PR Newswire February 2, 2016

Orexigen announces 2016 financial outlook and key priorities

PR Newswire January 11, 2016

Orexigen Therapeutics names Thomas Lynch as EVP, General Counsel & Secretary and Heather Ace as EVP, Global Human Resources

PR Newswire January 8, 2016

Orexigen Therapeutics to Speak at the J.P. Morgan 2016 Global Healthcare Conference

PR Newswire January 5, 2016

INVESTOR ALERT: 4 Stocks Under $10 With Increased Volatility

Accesswire December 7, 2015

Orexigen Therapeutics to Speak at the Piper Jaffray 27th Annual Healthcare Conference

PR Newswire November 25, 2015

Direction of Market Influences - Research on Orexigen, Cara Therapeutics, Uniqure and Baozun

Accesswire November 24, 2015

Looking into the Price Movements - Research on Agenus, Straight Path, Orexigen Therapeutics and Cara Therapeutics

Accesswire November 16, 2015

Orexigen Therapeutics to Present at Credit Suisse 2015 Healthcare Conference

PR Newswire November 6, 2015

Orexigen Therapeutics Reports Financial and Business Results for the Third Quarter Ended September 30, 2015

PR Newswire November 5, 2015

Technical Review of Stocks from Diverse Sectors - Research on Orexigen Therapeutics, Teligent, Tetraphase Pharmaceuticals and A10 Networks

Accesswire November 4, 2015

Orexigen Announces Naltrexone/Bupropion Data Presentations at ObesityWeek 2015

PR Newswire November 3, 2015

Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2015 Financial Results on November 5, 2015

PR Newswire October 22, 2015

Orexigen Announces Submission of Contrave® New Drug Application in South Korea

PR Newswire October 1, 2015

Orexigen Receives Payments Totaling $22 Million from U.S. and Korean Partners

PR Newswire September 23, 2015

Orexigen Raises $60 Million in Sale of Common Stock to Baupost

PR Newswire September 10, 2015